MX2021005345A - Composiciones y metodos. - Google Patents

Composiciones y metodos.

Info

Publication number
MX2021005345A
MX2021005345A MX2021005345A MX2021005345A MX2021005345A MX 2021005345 A MX2021005345 A MX 2021005345A MX 2021005345 A MX2021005345 A MX 2021005345A MX 2021005345 A MX2021005345 A MX 2021005345A MX 2021005345 A MX2021005345 A MX 2021005345A
Authority
MX
Mexico
Prior art keywords
compositions
methods
relates
viral vector
vector
Prior art date
Application number
MX2021005345A
Other languages
English (en)
Inventor
Sarah C Gilbert
Sarah Sebastian
Adrian V S Hill
Teresa Lambe
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of MX2021005345A publication Critical patent/MX2021005345A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

La invención se refiere a un vector viral que comprende ácido nucleico que tiene una secuencia de polinucleótido que codifica al menos un epítopo del antígeno Gly E del virus varicela-zóster (VZV), en donde dicho vector viral es un vector adenoviral. La invención también se refiere a usos, composiciones para usarse en tratamientos médicos y métodos de tratamiento médico.
MX2021005345A 2018-11-06 2019-11-05 Composiciones y metodos. MX2021005345A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1818084.4A GB201818084D0 (en) 2018-11-06 2018-11-06 Compositions and methods
PCT/GB2019/053131 WO2020095038A1 (en) 2018-11-06 2019-11-05 Compositions and methods

Publications (1)

Publication Number Publication Date
MX2021005345A true MX2021005345A (es) 2021-09-10

Family

ID=64655509

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005345A MX2021005345A (es) 2018-11-06 2019-11-05 Composiciones y metodos.

Country Status (12)

Country Link
US (1) US20220001007A1 (es)
EP (1) EP3876984A1 (es)
JP (1) JP2022506410A (es)
KR (1) KR20210090208A (es)
CN (1) CN113226364A (es)
AU (1) AU2019374480A1 (es)
CA (1) CA3118641A1 (es)
GB (1) GB201818084D0 (es)
MA (1) MA54143A (es)
MX (1) MX2021005345A (es)
SG (1) SG11202104448WA (es)
WO (1) WO2020095038A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
CN114081943B (zh) * 2021-11-08 2024-04-02 中国医学科学院医学生物学研究所 一种水痘-带状疱疹mRNA疫苗组合物及其制备方法和应用
CN114163503B (zh) * 2021-12-15 2023-11-24 北京交通大学 两种表达水痘-带状疱疹病毒的gE蛋白的重组腺病毒及应用
CN114703205A (zh) * 2022-03-11 2022-07-05 上海博唯生物科技有限公司 一种疱疹病毒糖蛋白gE重组蛋白、疫苗、制备方法和应用
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558586A1 (en) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University Recombinant varicella-zoster virus
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
RU2010105858A (ru) 2007-07-19 2011-08-27 Новавакс, Инк. (Us) Вирусоподобные частицы (vlp) вируса varicella zoster и антигены
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
KR101723605B1 (ko) 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
GB2549809C (en) * 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
WO2020030572A1 (en) * 2018-08-07 2020-02-13 Glaxosmithkline Biologicals Sa Processes and vaccines

Also Published As

Publication number Publication date
WO2020095038A1 (en) 2020-05-14
CA3118641A1 (en) 2020-05-14
KR20210090208A (ko) 2021-07-19
MA54143A (fr) 2022-02-16
EP3876984A1 (en) 2021-09-15
SG11202104448WA (en) 2021-05-28
AU2019374480A1 (en) 2021-05-27
JP2022506410A (ja) 2022-01-17
CN113226364A (zh) 2021-08-06
US20220001007A1 (en) 2022-01-06
GB201818084D0 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
MX2021005345A (es) Composiciones y metodos.
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
MX2018014573A (es) Vacuna contra el virus del zika.
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
WO2018195165A8 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
MX2017008186A (es) Anticuerpos humanos para la hemaglutinina de influenza.
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12015502164A1 (en) Flavivirus neutralizing antibodies and methods of use thereof
PH12016502554B1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
PH12016501444A1 (en) Antibodies against f glycoprotein of hendra and nipah viruses
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
MX2018006416A (es) Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina.
WO2020028719A3 (en) Compositions comprising herpes simplex virus-1 for use in methods of treating and preventing cancer
EA201990719A1 (ru) Новые промоторы
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
PH12017500419B1 (en) Recoded arbovirus and vaccines
WO2021019235A3 (en) Hantavirus antigenic composition
MX2022010372A (es) Vacuna contra la infeccion por el virus de la peste porcina africana.
PH12020551944A1 (en) Reverse peptide vaccine
MX2019007924A (es) Vacunas contra la influenza.
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с